Catalysts for Thea Pharma Inc
13 tracked
Apr 9, 2026
approval
COSOPT PF (DORZOLAMIDE HYDROCHLORIDE) — FDA approval
Cosopt
→
Feb 25, 2026
approval
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Nov 21, 2025
approval
AKTEN (LIDOCAINE HYDROCHLORIDE) — FDA approval
Laryng-O-Jet
→
Feb 28, 2022
approval
AKTEN (LIDOCAINE HYDROCHLORIDE) — FDA approval
Laryng-O-Jet
→
Sep 4, 2015
approval
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Sep 4, 2015
approval
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Mar 11, 2014
approval
AKTEN (LIDOCAINE HYDROCHLORIDE) — FDA approval
Laryng-O-Jet
→
Aug 28, 2013
approval
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Feb 22, 2013
approval
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Dec 7, 2012
approval
AKTEN (LIDOCAINE HYDROCHLORIDE) — FDA approval
Laryng-O-Jet
→
Feb 10, 2012
approval
ZIOPTAN (TAFLUPROST) — FDA approval
tafluprost
→
Feb 1, 2012
approval
COSOPT PF (DORZOLAMIDE HYDROCHLORIDE) — FDA approval
Cosopt
→
Oct 7, 2008
approval
AKTEN (LIDOCAINE HYDROCHLORIDE) — FDA approval
Laryng-O-Jet
→